Business Context and Reporting Period
Pavmed Inc. filed a Form 8-K Current Report on March 8, 2017, regarding unregistered sales of equity securities. The company is incorporated in Delaware and headquartered in New York, New York.
Key Financial Metrics
This filing reports on a specific capital raise event rather than periodic financial performance. Key metrics include:
- Units Issued: 171,504 Units
- Price per Unit: $6.00
- Gross Proceeds: $1,029,012
- Commissions Paid: $72,019.68
- Net Proceeds: $956,992.32 (before payment of other expenses)
The filing text does not provide values for revenue, profit, operating cash flow, margins, total debt, or liquidity ratios.
Material Changes
The material change reported is the issuance of additional equity under a Purchase Agreement originally disclosed on February 1, 2017. Each Unit consists of one share of Series A Convertible Preferred Stock and one Series A Warrant. Each Series A Warrant is exchangeable for four Series X Warrants, each exercisable for one share of common stock.
Outlook, Risks, and Unusual Items
The securities were offered and sold in a private placement pursuant to exemptions from registration requirements under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The filing includes a press release dated March 9, 2017, as an exhibit. No specific forward-looking guidance or risk factors beyond the standard private placement context are detailed in this text.
Investor Verification Checklist
- Verify the terms of the original Purchase Agreement filed on February 1, 2017, to understand the full scope of the capital raise.
- Confirm the conversion and exercise terms for the Series A Convertible Preferred Stock, Series A Warrants, and Series X Warrants.
- Review the March 9, 2017 press release (Exhibit 99.1) for additional context on the use of proceeds.
- Assess the dilution impact of the 171,504 Units and the associated warrants on existing shareholders.